Sotorasib in KRAS G12C-mutated non-small cell lung carcinoma

被引：0
|
作者：
Lorenz, Judith
机构：
来源：
PNEUMOLOGIE | 2023年 / 77卷 / 11期
关键词：
D O I：
10.1055/a-2111-0905
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Menschen mit einem fortgeschrittenen nichtkleinzelligen Lungenkarzinom (NSCLC) haben eine schlechte uberlebensprognose. Liegt eine KRAS G12C-Mutation vor, profitieren sie den Ergebnissen der CodeBreak 100-Studie zu Folge von Sotorasib, einem spezifischen und irreversiblen KRAS-Inhibitor. Nun berichten die Studieninitiatorinnen und -initiatoren die 2-Jahres-Datenauswertung bezuglich der Effektivitat, der Sicherheit sowie molekularer Biomarker.
引用
收藏
页码：846 / 846
页数：1
相关论文
共 50 条
  • [31] CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC
    Clarke, J. M.
    Felip, E.
    Li, B. T.
    Ruffinelli, J. C.
    Garrido, P.
    Zugazagoitia, J.
    Goldberg, S. B.
    Ramalingam, S. S.
    Victoria, I.
    Puri, S.
    Gandara, D. R.
    Varrieur, T.
    Edmonds, S.
    Palmer, K.
    Snyder, W.
    Govindan, R.
    Rybkin, I.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S118 - S119
  • [32] Garsorasib in KRAS G12C-Mutated Non-Small-Cell Lung Cancer: Updated Results from a Phase 2 Study
    Li, Z.
    Lu, S.
    Dang, X.
    Huang, D.
    Jin, S.
    Li, W.
    Shi, J.
    Wang, X.
    Zhang, Y.
    Song, Z.
    Zhang, J.
    Zhuang, W.
    Liu, X.
    Jiang, L.
    Meng, X.
    Zhao, M.
    Zhou, J.
    Zhang, L.
    Wang, P.
    Luo, H.
    Yang, J.
    Cang, S.
    Wang, X.
    Wang, J.
    Cui, J.
    Yu, Y.
    Zhang, Z.
    Lu, J.
    Yang, W.
    Li, G.
    Feng, J.
    Lv, D.
    Wu, L.
    Fang, Y.
    Wang, Y.
    Zhao, Y.
    Cao, B.
    Zhu, W.
    Zhuang, Z.
    Li, Q.
    Wang, M.
    Zhou, H.
    Dong, X.
    Hu, S.
    Fang, J.
    Xu, C. -W.
    Wang, W.
    Xiang, Z.
    Shi, Z.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S40 - S41
  • [33] Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer
    Pellini, B.
    Ganesan, V.
    Wan, F.
    Sankararaman, S.
    Manyanont, S.
    Akhave, N.
    Baggstrom, M.
    Ward, J.
    Waqar, S.
    Morgensztern, D.
    Govindan, R.
    Devarakonda, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S209 - S210
  • [34] Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
    Yamada, T.
    Morimoto, K.
    Hirai, S.
    Katayama, Y.
    Kunimasa, K.
    Sasaki, T.
    Nishida, M.
    Watanabe, S.
    Shiotsu, S.
    Uehara, H.
    Takayama, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S194 - S194
  • [35] Clinical utility of circulating tumor DNA in patients with advanced KRAS G12C-mutated NSCLC treated with sotorasib
    Ernst, Sophie M.
    van Marion, Ronald
    Atmodimedjo, Peggy N.
    de Jonge, Evert
    Mathijssen, Ron H.
    Paats, Marthe S.
    de Bruijn, Peter
    van Schaik, Ron H. N.
    Dubbink, Hendrikus J.
    Dingemans, Anne-Marie C.
    CANCER RESEARCH, 2023, 83 (07)
  • [36] Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond
    Gray, Jhanelle E.
    Hsu, Hil
    Younan, Diana
    Suri, Gaurav
    Chia, Victoria
    Spira, Alexander
    Johnson, Melissa
    LUNG CANCER, 2023, 181
  • [37] KRAS G12C mutations in non-small cell lung cancer
    Li, J. J.
    Wu, X. J.
    Farzin, M.
    Bray, V.
    Williamson, J.
    Pal, A.
    Yip, P. Y.
    Hagelamin, A.
    Ding, P.
    Nindra, U.
    Vinod, S.
    French, B.
    Chua, W.
    Gupta, R.
    Cooper, W. A.
    Wang, B.
    Lee, C. S.
    HISTOPATHOLOGY, 2024, 85 : 25 - 25
  • [38] Sotorasib in KRAS p.G12C-mutated NSCLC
    Gassa, Asmae
    Oezkan, Filiz
    Bruns, Christiane
    Schmidt, Thomas
    Alakus, Hakan
    ONKOLOGE, 2021, 27 (10): : 1031 - 1032
  • [39] Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Gadgeel, S.
    Rahman, A.
    Osaghae, U.
    Fernando, T. M.
    Lin, M. T.
    Koli, K.
    Meyenberg, C.
    Mathisen, M.
    Skoulidis, F.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S349 - S349
  • [40] The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C
    Notario Rincon, L.
    Pous, A.
    Lopez-Paradis, A.
    Cerda, G.
    Cucurull, M.
    Hernandez, A.
    Domenech, M.
    Carcereny, E.
    Moran Bueno, M. T.
    Munoz, A.
    Mate, J. L.
    Sanz, C.
    Saigi, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S50 - S50
12345